Edgewise Therapeutics, Inc.EE

Edgewise Therapeutics, Inc.

22.00USDR
−1.27−5.46%
Last update at 21:02 GMT
USD
No tradesPost-market
See on Supercharts

EWTX fundamentals

Key facts

Market capitalization‪2.09 B‬USD
Basic EPS (TTM)−1.45USD
Founded2017
CEOKevin Koch
About

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Ownership
‪‪95.21 M‬‬
Free Float shares
‪‪67.23 M‬‬ (70.62%)
Closely held shares
‪‪27.97 M‬‬ (29.38%)
Free Float shares
‪‪67.23 M‬‬ (70.62%)
Closely held shares
‪‪27.97 M‬‬ (29.38%)
Capital structure
Market cap
‪‪2.09 B‬‬
Debt
‪‪4.74 M‬‬
Cash & equivalents
‪‪470.17 M‬‬
Enterprise value
‪‪1.63 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪2.09 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Valuation ratios
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24

Growth and Profitability

Company’s recent performance and margins

Performance
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−40.00 M‬‬
‪‪−30.00 M‬‬
‪‪−20.00 M‬‬
‪‪−10.00 M‬‬
‪0.00‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−48.00 M‬‬
‪‪−36.00 M‬‬
‪‪−24.00 M‬‬
‪‪−12.00 M‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−40.00 M‬‬
‪‪−30.00 M‬‬
‪‪−20.00 M‬‬
‪‪−10.00 M‬‬
‪0.00‬

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
Actual
Estimate
Earnings
Next:May 8, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪−0.44‬
‪−0.33‬
‪−0.22‬
‪−0.11‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

EWTX does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−30.00 M‬‬
‪0.00‬
‪‪30.00 M‬‬
‪‪60.00 M‬‬
‪‪90.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪120.00 M‬‬
‪‪240.00 M‬‬
‪‪360.00 M‬‬
‪‪480.00 M‬‬
Assets
Liabilities